QPPV.COM KNOWLEDGE ASSESSMENT

Bispecific and Multispecific Antibodies: Biology, Clinical Development and Pharmacovigilance

Test your understanding of the concepts covered by Bispecific and Multispecific Antibodies: Biology, Clinical Development and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A dual-pathway bispecific produces an adverse reaction not seen with either parental antibody alone. What is the best initial safety interpretation?

The event must be unrelated because each individual target is already clinically characterised The event may reflect additive, synergistic or qualitatively new effects from simultaneous target engagement The event proves that the product is contaminated The event should be assigned automatically to the target with the higher affinity

Question 2 of 10 Why should all neurological adverse-event terms reported with a bispecific not automatically be classified as ICANS?

ICANS is unrelated to immune-effector therapies Neurological manifestations may have alternative or contributing causes, including infection, metabolic abnormalities, CNS disease or concomitant medicines ICANS can occur only after permanent treatment discontinuation Preferred terms always provide more clinical information than medical review

Question 3 of 10 Which statement best characterises the non-clinical relevance of an animal species for a bispecific antibody?

Species relevance is established if either binding arm recognises its target A species is informative only when both required target engagements and their functional consequences are sufficiently comparable Any primate study is automatically predictive for a bispecific antibody A species is relevant if the product has an Fc region, regardless of target binding

Question 4 of 10 Which factor would be least relevant when assessing the likelihood and severity of CRS with a T-cell-engaging bispecific?

Tumour burden and circulating target-cell burden The exact dose and position within a step-up sequence Binding geometry and affinity of the two arms Whether the molecule has two binding specificities rather than one, irrespective of its mechanism

Question 5 of 10 A safety reviewer is comparing two products that bind the same target pair. Which conclusion is most scientifically appropriate?

They can be treated as clinically equivalent because the targets are identical Their safety profiles should be assumed to match unless disproven by spontaneous reports Their architectures, affinities, valencies, exposure profiles and clinical contexts may produce different risks Only their brand names need to be distinguished in aggregate analysis

Question 6 of 10 Why can a small Fc-free T-cell engager still present substantial systemic risk?

Small size guarantees rapid accumulation in all tissues Short plasma half-life prevents inflammatory effects Potent cell-bridging can trigger rapid immune activation, including self-amplifying inflammatory responses Fc-free molecules are intrinsically more immunogenic than all IgG-like molecules

Question 7 of 10 What is the most important pharmacovigilance reason to record the exact dose within a step-up sequence?

The maintenance dose is always the cause of first-dose reactions The initiating exposure and timing may differ substantially between step-up doses and the nominal maintenance dose Step-up doses are administrative details with no relationship to risk It allows all products to be pooled under a common dosing category

Question 8 of 10 Which interpretation most accurately describes the term “bispecific” for pharmacovigilance purposes?

It identifies a uniform safety class with predictable adverse reactions It describes an architectural property that requires further assessment of format, targets and mechanism It means that the product contains two conventional monoclonal antibodies administered together It indicates that the product has exactly two pharmacological effects

Question 9 of 10 Which statement best explains the importance of manufacturing-change traceability for a bispecific antibody?

Manufacturing changes cannot affect clinical safety if the amino-acid sequence is unchanged Traceability allows possible changes in binding, potency, immunogenicity or unintended immune activation to be investigated by product period and batch Batch information is relevant only for counterfeit investigations Spontaneous reports always contain sufficient batch information for comparability assessment

Question 10 of 10 A patient develops an infection several weeks after switching from one B-cell-directed bispecific to another. Which attribution approach is most appropriate?

Attribute the event exclusively to the newest product because it was the last administered treatment Attribute the event exclusively to the previous product because immune depletion began earlier Assess the temporal relationship and cumulative effects of both products, including residual pharmacology, immune status and prophylaxis Exclude the case because switching makes causality impossible

QPPV.com

Bispecific and Multispecific Antibodies: Biology, Clinical Development and Pharmacovigilance

Cookie Settings